This study is looking at whether taking MitoQ for six months can help people with Peripheral Arterial Disease (PAD), specifically those who experience leg pain when walking (intermittent claudication). We want to see if MitoQ helps you walk further, be more active daily, and improve your overall quality of life. We'll also examine how MitoQ affects the health of your leg muscles and tiny blood vessels. You might be able to join if you are 21 or older, have a history of chronic claudication, and have documented lower extremity arterial occlusive disease. The main goal is to see if MitoQ improves your maximum walking distance on a treadmill after six months. The current status of this study is unclear, and it plans to enroll 60 participants.

Study design

This interventional study plans to enroll 60 participants. It will compare MitoQ treatment to a placebo over six months.

What's involved

You will undergo walking assessments, quality of life surveys, leg blood pressure measurements, muscle oxygen evaluations, and blood tests at the start and after six months of treatment.

Compensation

Not stated in the trial record.

Follow-up

You will be assessed at baseline and after six months of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.